Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown positive results in heart failure patients with obesity. The drug reduced hospitalizations, need for increased heart failure medication, and mortality due to heart complications by 38% compared to a placebo in a 52-week trial. Patients also reported improvements in symptoms like shortness of breath, fatigue, and leg swelling. These findings add to the growing body of evidence that GLP-1 drugs, including tirzepatide, have benefits beyond just treating diabetes and weight loss.
Currently, options for treating heart failure have been limited, making tirzepatide a potentially valuable addition to the treatment toolbox. The drug has shown to improve symptoms, functional capacity, and quality of life in heart failure patients, marking a significant advancement in the field. Tirzepatide may also help reduce epicardial fat and inflammation around the heart, which could contribute to its effectiveness in treating heart failure.
This study specifically looked at patients with heart failure with preserved ejection fraction, a condition that affects many heart failure patients. Approximately 60% of these patients also have obesity, highlighting the potential impact of a drug like tirzepatide in this population. Furthermore, earlier studies have shown that tirzepatide can reduce sleep apnea in adults with obesity, indicating its broader potential in addressing various health issues.
Overall, the results suggest that tirzepatide, along with other GLP-1 drugs, could be a game-changer in the treatment of heart failure and related complications, offering new hope for patients with limited therapeutic options.
Photo credit
www.nbcnews.com